FDA’s AI Warning: De-Risking Due Diligence for Cardiac AI Investors

The Food and Drug Administration’s (FDA) Warning Letter to Exer Labs represents a pivotal moment for the burgeoning private AI health sector. For venture capitalists, growth equity firms, and SEC regulatory officers assessing pre-IPO digital health AI companies, this enforcement action is not merely an isolated incident but a critical signal regarding regulatory risk and the foundational due diligence required for market entry and sustained growth. Understanding the nuances of this first significant regulatory intervention is paramount to accurately valuing and de-risking investments in this space.

The Exer Labs Warning Letter: A Bellwether for Regulatory Scrutiny

The FDA’s action against Exer Labs, specifically through the Center for Devices and Radiological Health (CDRH), underscores a clear regulatory expectation: digital health products making medical claims, regardless of their technological sophistication, must adhere to established medical device regulations. Exer Labs’ product, which claimed to assess body composition and other health metrics using AI-powered motion analysis, was deemed by the FDA to be a medical device requiring premarket clearance or approval. The core issue was the company’s failure to obtain such authorization before marketing its product with diagnostic and screening claims. This enforcement action highlights a critical distinction that many AI health startups, and by extension their investors, may have overlooked or underestimated: the line between a general wellness product and a regulated medical device. The implications for investor diligence are profound. Companies relying on AI to deliver health insights must demonstrate a clear understanding of, and compliance with, the regulatory pathways relevant to their specific claims and functionalities. As Bakul Patel, a widely recognized authority in digital health regulation, has often emphasized, the FDA’s approach is rooted in the risk presented to patients. Devices that provide diagnostic information or guide treatment decisions inherently carry higher risk and thus require more stringent oversight. The Exer Labs case serves as a stark reminder that the FDA’s enforcement arm is willing to act when companies cross this line without proper authorization.

Navigating the FDA’s SaMD Framework: A Due Diligence Imperative

For any private AI health company eyeing a public offering or significant growth capital, a robust regulatory strategy grounded in the FDA’s Software as a Medical Device (SaMD) Framework is no longer optional; it is a foundational pillar of valuation. The SaMD Framework provides a structured approach to classify software based on its intended use and the significance of the information it provides to healthcare decisions. The Exer Labs warning illustrates the perils of misclassifying a product. Had Exer Labs proactively engaged with the FDA or correctly identified their product as SaMD requiring premarket authorization, they could have potentially avoided this enforcement action. Investors must scrutinize a company’s regulatory posture, asking critical questions:

• Has the company accurately classified its AI-powered product within the SaMD framework?
• What premarket pathways (e.g., 510(k) clearance, De Novo classification, PMA) are applicable, and what is the company’s progress on these?
• Does the company have a Quality Management System (QMS) in place, such as ISO 13485, suitable for a regulated medical device? ISO 13485 standard overview
• How does the company plan to manage algorithmic drift and demonstrate ongoing safety and effectiveness post-market?

These questions are not merely compliance checkboxes; they are indicators of a company’s operational maturity and its ability to scale responsibly within a regulated environment. A company that demonstrates a clear understanding of its regulatory obligations and a proactive approach to compliance signals a de-risked asset to potential investors.

Beyond the Warning Letter: Proactive Regulatory De-Risking

The Exer Labs incident should serve as a catalyst for a more rigorous approach to regulatory due diligence in the private AI health investment landscape. While the FDA Exer Labs Warning Letter specifically addressed an unapproved device, its broader message encompasses the need for transparency, scientific rigor, and patient safety in all digital health offerings. For VCs and growth equity firms, this means moving beyond a cursory review of regulatory filings. It requires a deep dive into the company’s product development lifecycle, clinical validation strategy, and post-market surveillance plans. Companies that invest in robust clinical evidence generation, even for products that might initially seem low-risk, are building a stronger foundation. This includes:

• Publishing outcomes data in peer-reviewed journals, demonstrating the clinical utility and effectiveness of their AI solutions.
• Establishing enterprise contract breadth with major health systems and demonstrating health plan penetration, which often requires robust evidence of efficacy and cost-effectiveness.
• Engaging early and often with the FDA CDRH to clarify regulatory pathways and expectations.

Bakul Patel’s past guidance on the importance of “building quality in” from the outset resonates strongly here. Bakul Patel’s insights on digital health regulation Companies that view regulatory compliance as an integral part of product development, rather than a hurdle to overcome, are better positioned for long-term success and attract more confident investment. Data points like the data, which presumably relate to the scale of non-compliant marketing or user exposure, would further underscore the FDA’s commitment to protecting public health from unvalidated claims.

The Investment Landscape: A New Regulatory Baseline

The FDA Exer Labs Warning Letter has undeniably raised the regulatory baseline for private AI health companies. For investors, the “path-to-public assessment” now includes a more stringent evaluation of regulatory readiness and risk mitigation strategies. Companies seeking pre-IPO funding must demonstrate not only innovative technology and market potential but also a clear, executable plan for navigating the complex regulatory environment. The absence of a clear regulatory strategy, or worse, a history of non-compliance, will increasingly become a significant valuation detractor. Conversely, companies that proactively embrace regulatory requirements, demonstrating a mature understanding of the FDA SaMD Framework and a commitment to patient safety, will stand out as more attractive investment opportunities. The era of “move fast and break things” in digital health is unequivocally over, replaced by a mandate for responsible innovation. This first enforcement action by the FDA CDRH is not a deterrent to investment in AI health, but rather a clarifying event, defining the guardrails within which sustainable growth and innovation can thrive. FDA CDRH digital health guidance For the best private AI health companies and top private digital health companies, robust regulatory compliance will be as critical a valuation signal as market traction and technological superiority.